相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy
Lawrence D. Kaplan et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
Nanoparticle multivalency counterbalances the ligand affinity loss upon PEGylation
Robert Hennig et al.
JOURNAL OF CONTROLLED RELEASE (2014)
High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems
Alexandre Albanese et al.
ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 14 (2012)
Doxil® - The first FDA-approved nano-drug: Lessons learned
Yechezkel (Chezy) Barenholz
JOURNAL OF CONTROLLED RELEASE (2012)
Development of Pegylated Liposomal Vincristine Using Novel Sulfobutyl Ether Cyclodextrin Gradient: Is Improved Drug Retention Sufficient to Surpass DSPE-PEG-Induced Drug Leakage?
Jingxia Cui et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Recent Advances in Cancer Therapy: An Overview
A. Urruticoechea et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Phase 1 Multicenter Study of Vincristine Sulfate Liposomes Injection and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
Deborah A. Thomas et al.
CANCER (2009)
Vincristine Sulfate Liposomes Injection (Marqibo) in Heavily Pretreated Patients With Refractory Aggressive Non-Hodgkin Lymphoma Report of the Pivotal Phase 2 Study
M. A. Rodriguez et al.
CANCER (2009)
Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine
Charles O. Noble et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Tumor targeting of vincristine by mBAFF-modified PEG liposomes in B lymphoma cells
Li Zhang et al.
CANCER LETTERS (2008)
A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma
Agop Y. Bedikian et al.
MELANOMA RESEARCH (2008)
Release of drugs from liposomes varies with particle size
Masahiro Yamauchi et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2007)
Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin
Michael J. W. Johnston et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2007)
Conventional liposome performance and evaluation: Lessons from the development of vescan
Gerard M. Jensen et al.
JOURNAL OF LIPOSOME RESEARCH (2007)
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
DE Owens et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2006)
Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia
DA Thomas et al.
CANCER (2006)
Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations
MJW Johnston et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2006)
PEGylation, successful approach to drug delivery
FM Veronese et al.
DRUG DISCOVERY TODAY (2005)
Liposome-encapsulated vincristine, vinblastine and vinorelbine: A comparative study of drug loading and retention
IV Zhigaltsev et al.
JOURNAL OF CONTROLLED RELEASE (2005)
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077B103) in a preclinical tumor model of melanoma
WC Zamboni et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial
AH Sarris et al.
ANNALS OF ONCOLOGY (2000)
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
H Maeda et al.
JOURNAL OF CONTROLLED RELEASE (2000)
分享论文
